Two peer-reviewed studies published in the last 12 months suggest it may also be a geroprotective agent, a compound that addresses multiple hallmarks of biological aging simultaneously.
The Emory and Baylor study found that psilocin reduces oxidative stress, improves DNA repair responses, and preserves telomere length.
These are mechanisms of cellular aging, not of consciousness or mood.
The Italian study identified the 5-HT2B receptor, distributed throughout the liver, gut, and metabolic tissue, as the driver of the metabolic effects.
Pcybin acted on peripheral receptors at doses producing no detectable central nervous system effects.
The psycdelic experience wasn't required.
The same study documented improved muscle strength and near-complete normalization of disrupted hepatic lipid pathways.
That finding has a practical implication: if the therapeutic effects on metabolism and aging occur without engaging the central nervous system, developing non-psycadelic doses as conventional treatments becomes a considerably clearer path.
Most pharmaceutical longevity candidates are single-target interventions.
This appears to be operating across multiple systems at once.
Bryan Johnson's data is n=1 and carries no clinical weight alone.
But the biomarker pattern, lower systemic inflammation, HPA axis reset, improved glucose regulation, is consistent with what the preclinical research would predict.
The compound has been growing in forest soil for millions of years. The classification is recent.
Sources:
Kato et al. npj Aging 2025 - doi.org/10.1038/s41514-025-00244-x
Colognesi et al. Pharmacological Research 2026
blueprint.bryanjohnson.com/blogs/news/magic-mushroom-biomarker-results